🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Scor slumps after warning from life & health business

Published 2024-07-16, 09:20 a/m
© Reuters.
SCOR
-

Investing.com - Scor (EPA:SCOR) stock slumped Tuesday after the French reinsurer issued a profit warning due to actions taken in its life & health business.

At 09:15 ET (13:15 GMT), Scor shares fell 25% to €19.45, dropping to its lowest levels this year. 

“Following the negative experience variance in the first quarter of 2024, Scor has decided to accelerate the annual L&H reserving assumptions review, and to include a best estimate view in the Q2 2024 results,” the company said in a press release.

Scor added that the second quarter L&H insurance service result is expected at around -€0.4 billion.

“Today’s communication is consistent with Scor’s proactive and transparent communication policy. Following the accelerated L&H reserving assumptions review, we have decided to launch the first of a series of determined actions aimed at restoring the profitability of our L&H business in a sustainable way,” said CEO Thierry Leger.

The good news is that the group's solvency remains >200% and therefore within the target range (180%-220%), said analysts at Jefferies, in a note.

“Moreover, liquidity is unimpacted, and future earnings volatility is potentially mitigated. The only reference to P&C is that "they continue to deliver a very strong performance", which bodes well for underlying margins,” Jefferies added. “In this regard though, we remain concerned that the catastrophe loss ratio will exceed the 2Q budget and thus be in line for 1H (after a benign 1Q).”

Jefferies maintained a ‘hold’ rating, and a €27 price target.

“The added risk now is that an active U.S. hurricane season, could adversely impact the Solvency position further. While Scor states there is no impact to liquidity or dividend policy in today's release, that will likely be little consolation at this stage of the hurricane season in our view,” UBS added, in a note.

UBS maintained a ‘buy’ rating, with a 12-month price target of €33.70.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.